Biogen (BIIB) – Trade Idea

Company Description

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. Source: Reuters


Option Pricing

  • Implied Volatility (expected price movement) for short-dated options is 40%
  • Realized Volatility (historic price movement) for short-dated options is 86%
  • Implied Volatility Percentile for short-dated options is 95%

Trade Idea

Yesterday the company surprised traders with plans to (re)submit its Alzheimer’s treatment for regulatory approval in the U.S. On the back of this news BIIB shares closed up 26.1% at $281.87. Should yesterday’s significant rebound hold, numerous analysts could upwardly revise their price targets on BIIB. The consensus 12-month price target of $256.85 now stands at ~9% discount to current levels, suggesting price-target hikes could be on the horizon. If you are bullishly inclined one could trade current bullish momentum in an intelligent and risk-defined manner such as:

Buy115 Nov290Call
Sell115 Nov295Call
Buy115 Nov300Call
Sell115 Nov305Call


  • Break-even on expiration: 293.40
  • Max loss of $3.40 at or below 290 
  • Max gain of $6.60 at or above 305

PnL Graph

This website is a general communication being provided for informational purposes only. It is educational in nature and not designed to be a recommendation for any specific investment product, strategy, plan feature or other purposes. By receiving this communication you agree with the intended purpose described above. Any examples used in this material are generic, hypothetical and for illustration purposes only. None of EQT Media, its affiliates or representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. Communications such as this are not impartial and are provided in connection with the advertising and marketing of products and services. Prior to making any investment or financial decisions, an investor should seek individualized advice from a personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor’s own situation. Opinions and statements of financial market trends that are based on current market conditions constitute our judgment and are subject to change without notice. We believe the information provided here is reliable but should not be assumed to be accurate or complete. The views and strategies described may not be suitable for all investors. This communication may not be redistributed or retransmitted, in whole or in part, or in any form or manner, without the express written consent of EQT Option. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute or retransmit the contents and information contained in this communication without first obtaining express permission from an authorized officer of EQT Option.